Peptide · Healing & recovery
Body Protection Compound-157 is a synthetic peptide derived from a protective protein found in human gastric juice. Studied primarily for soft-tissue healing.
Body Protection Compound-157 is a synthetic peptide derived from a protective protein found in human gastric juice. Studied primarily for soft-tissue healing.
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide that is a synthetic fragment of a larger protective protein (BPC) found in human gastric juice. The proposed mechanisms involve nitric oxide pathway modulation, growth-hormone receptor upregulation, VEGFR2 signaling supporting angiogenesis (new blood vessel formation), and modulation of dopaminergic and serotonergic systems. The angiogenesis hypothesis is the most-cited explanation for the soft-tissue healing effects observed in animal models.
Most evidence is preclinical, predominantly animal models. Human data are limited.
Not FDA-approved. October 2023 FDA classification placed BPC-157 on the 503A bulk substances Category 2 list, restricting compounding.
Common research and clinical-use protocols:
Actual dosing should always be set by a prescribing clinician.
Dosing in research and clinical-use contexts varies. Specific protocols should always be set by a prescribing clinician, not by patient-direct sources.
Reported side effects in clinical use are generally mild: injection-site irritation, mild fatigue in the first 1–2 weeks, occasional nausea. Pre-clinical safety studies have not flagged organ toxicity at typical doses. Important: human safety data is limited; long-term safety is not well characterized. The October 2023 FDA classification placing BPC-157 on the 503A bulk substances Category 2 list reflects insufficient data to support routine compounding.
BPC-157 is most commonly stacked with TB-500 for soft-tissue healing protocols (synergistic mechanisms — BPC-157 supports angiogenesis, TB-500 supports actin remodeling). Some protocols add GHK-Cu for additional tissue-repair signaling. Patients pursuing growth-hormone optimization sometimes layer ipamorelin/CJC-1295 alongside BPC-157 for systemic recovery support.
Most peptides discussed on this page are compounded products requiring a prescription from a licensed clinician. Reputable telehealth peptide programs include physician-led oversight, accredited compounding pharmacies, and clear regulatory framing. For weight-management GLP-1 programs, see our provider reviews.
Body Protection Compound-157 is a synthetic peptide derived from a protective protein found in human gastric juice. Studied primarily for soft-tissue healing.
Not FDA-approved. October 2023 FDA classification placed BPC-157 on the 503A bulk substances Category 2 list, restricting compounding.
Uses include: Tendon and ligament repair (research), Gut barrier support (research), Anti-inflammatory effects (research). This is research and clinical-use context, not a recommendation. Always work with a licensed clinician.
Most evidence is preclinical, predominantly animal models. Human data are limited.
Reported dosing: 250–500 mcg subcutaneous, 1–2× daily, 4–8 week cycles (research context). Actual dosing should always be determined by your prescribing clinician, not by online sources.
BPC-157 is not approved by the FDA. The October 2023 FDA classification placed BPC-157 on the 503A bulk substances Category 2 list, which restricts its use in compounding. Check current FDA guidance and your state's regulations before pursuing access.
Reported timelines from clinical use are 2–6 weeks for early effects, with most protocols running 6–8 weeks. This is anecdotal — there are no published RCTs in humans confirming these timelines.
Oral BPC-157 may have local GI effects, but systemic bioavailability is much lower than subcutaneous injection. For tendon/ligament work, injection is the preferred route in clinical practice.